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Activation of the sympathetic nervous system, manifested
by an increase in plasma norepinephrine (NE), is a salient
feature in congestive heart failure (HF). This was first
thought to be an important adaptive mechanism to support
the failing myocardium (1). However, evidence now indi-
cates that activation of the sympathetic nervous system is
detrimental and maladaptive. Long-term exposure of the
heart to NE can cause not only myocardial -adrenoceptor
down-regulation but also cardiac hypertrophy, ischemia,
cardiac arrhythmia, tissue necrosis, and myocyte apoptosis,
all of which have been shown in patients with congestive
HF (2). This concept is further supported by several large
clinical trials showing that long-term -blocker therapy can
not only improve left ventricular (LV) systolic function but
also increase survival in patients with chronic HF secondary
to LV systolic dysfunction (3–5).
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Given the overwhelming success of the -adrenoceptor
blocker therapy, several investigators have looked into the
possibility that more effective therapy can be derived by
silencing the sympathetic nervous system activity with
sympatholytic agents such as moxonidine and clonidine.
Unlike clonidine, which acts on the central -2 adrenergic
receptors, moxonidine preferentially stimulates the brain
stem imidazoline-1 receptor to decrease sympathetic out-
flow (6). Although both agents have been shown to reduce
plasma NE and produce some benefits in patients with HF
(7–9), the long-term Moxonidine Congestive Heart Failure
(MOXCON) trial was terminated prematurely because of
increased mortality in the moxonidine group (10). Similarly,
a subgroup analysis of the Beta Blocker Evaluation of
Survival Trial (BEST) showed that those subjects who died
during the study had higher plasma NE concentration at
baseline and greater reductions of plasma NE after three
months of bucindolol treatment than subjects who survived
(11). It was speculated that bucindolol has an effect on the
central nervous system that suppresses the sympathetic
outflow (11). The authors conclude that sympatholytic
agents should be given with caution to patients with severely
compromised hemodynamics in whom a critical minimal
adrenergic tone is important. The findings suggest that the
sympathetic nervous system activation can be both adaptive
and maladaptive, depending on the degree of basal sympa-
thetic activation and the extent of sympatholysis.
In this issue of the Journal, Igawa et al. (12) report a study
in which three doses of guanethidine were used to produce
dose-dependent decreases of plasma NE in rats with HF
after myocardial infarction. Guanethidine was started two
days before coronary occlusion and continued for 28 days
after myocardial infarction. All three doses of guanethidine
improved the short-term survival after coronary artery
occlusion, but only the low-dose guanethidine (1 mg/kg/
day) reduced LV dilation and improved LV mechanical
function and survival over 28 days. When the high dose of
guanethidine (10 mg/kg/day) was administered, only three
of 34 rats survived four weeks. An intermediate dose of
guanethidine produced no beneficial effects on either cardiac
hemodynamics or four-week mortality compared with the
control group. Results of the study indicate that the effects
of sympatholytic agents are dose-dependent and that exces-
sive sympathetic inhibition may be deleterious in HF.
However, unlike bucindolol in the BEST study, long-
term use of carvedilol reduced cardiovascular mortality and
morbidity in patients with very severe HF in whom removal
of the noradrenergic drive by -receptor blockade was
expected to exert a negative effect (13). Thus fundamental
differences may exist between sympatholysis and -receptor
blockade in their delivery of an anti-adrenergic effect.
Furthermore, unlike moxonidine and bucindolol, guaneth-
idine acts on the peripheral sympathetic nerves to reduce
NE release. Ultrastructural and immunohistologic changes
such as those produced by immune-mediated neuronal
degeneration have been shown to occur in the peripheral
sympathetic nerves after guanethidine treatment (14,15).
This raises a question whether the harmful effects of
guanethidine reported in the study by Igawa et al. (12) were
related to destruction of the cardiac sympathetic nerves.
Recently, radio-iodinated metaiodobenzylguanidine
(123I-MIBG), a structural analogue of NE, has been used to
study the integrity and function of the cardiac sympathetic
nervous system (16). The failing heart is characterized by
reduced washout and distribution of MIBG on myocardial
scintigraphy. Studies have shown that cardiac sympathetic
nerve innervation as demonstrated by MIBG scintigraphy is
an independent predictor for fatal outcomes in patients with
HF (17). More importantly, the beneficial effects of carve-
dilol (18), metoprolol (19), spironolactone (20), and enala-
pril (21) are associated with improvements in cardiac sym-
pathetic innervation. In contrast, bucindolol therapy, which
showed only marginal survival benefits (22), did not im-
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prove the sympathetic nerve function as measured by MIBG
(23).
Our laboratories have studied the pre- and post-synaptic
changes of the cardiac sympathetic nerve function in exper-
imental HF. We were the first to demonstrate a chamber-
specific reduction of myocardial -receptors, occurring only
in the failing right ventricle of dogs with right-heart failure
produced by tricuspid avulsion and progressive pulmonary
artery constriction (24). The decrease of myocardial
-adrenoceptor density is linked to reduced NE uptake
activity, NE uptake-1 carrier density (25,26), and increased
interstitial NE (27). Furthermore, because myocardial NE
uptake is also reduced by exogenous NE administration, we
speculate that the changes of the sympathetic nerve terminal
function in HF are caused by the increased interstitial NE
concentration (27). The functional importance of the NE
uptake site was further studied in rabbits at various time
intervals after the start of rapid ventricular pacing (28). We
found that rapid ventricular pacing caused early sympathetic
nervous system activation, followed in sequence by reduced
myocardial NE uptake, loss of neuronal NE, and down-
regulation of myocardial -adrenoceptors. In addition,
long-term use exogenous NE has been shown to reduce
myocardial NE uptake and -adrenoceptor receptor density
in normal animals without HF (29). The interdependence
of increased sympathetic stimulation, decreased cardiac NE
uptake, and myocardial -adrenoceptor down-regulation is
further borne out by a recent study by Leineweber et al.
(30), who found that neurohumoral activation is essential
for the reduction of myocardial -receptors in the hyper-
trophied right ventricle produced by monocrotaline, which,
similar to our earlier studies in right-heart failure (24,25), is
characterized by a chamber-specific reduction of myocardial
NE uptake sites (31).
The functional importance of the NE reuptake mecha-
nism in the regulation of myocardial -receptor density and
post-synaptic -adrenergic inotropic responsiveness was
further studied in the right-heart-failure animals treated
with desipramine (32). Unlike guanethidine, desipramine
blocks neuronal uptake of NE at the sympathetic nerve
terminals without destroying sympathetic nerves. We found
that desipramine facilitated the reduction of myocardial
-adrenoceptor density and -adrenergic subsensitivity in
the animals. In contrast, selegiline, which is a central
2-agonist with a neuroprotective effect, attenuated the
increase in plasma NE and the decrease of myocardial
-receptor density and improved cardiac mechanical func-
tion in pacing-induced cardiomyopathy (33). Selegiline also
prevented the reductions of NE uptake activity, NE
uptake-1 carrier site density, and sympathetic neurotrans-
mitter profiles in the failing heart.
Our studies suggest a revised paradigm for the treatment
of congestive HF. While interventions should be directed
toward minimizing the noradrenergic release of NE or
blocking the harmful apoptotic and oxidative effects of NE
on the sympathetic nerves and cardiomyocytes in HF,
attention should be paid to preserving the integrity and NE
reuptake function of the sympathetic nerve terminals.
Guanethidine produces marked inhibition of the sympa-
thetic nerve activity and plasma NE, but at high doses it also
exerts a negative effect on the functional integrity of the
sympathetic nerve terminals. Cardiac interstitial NE may
have increased further and contributed to the clinical ad-
verse effects of guanethidine (12). Whether moxonidine
affects NE uptake or storage in the sympathetic nerve
terminals is not known. In addition to selegiline, guana-
benz—also an 2-agonist—has been shown to improve
cardiac sympathetic NE and tyrosine hydroxylase activity in
animals with aortic constriction (34). At least three different
presynaptic 2 receptors have been identified and shown to
control NE release in HF at present. Brede et al. (35)
reported recently that progression of HF produced by aortic
constriction was worsened in gene-targeted mice lacking
either an 2A or an 2C receptor subtype but not in mice
lacking the 2B receptor subtype. It is clear that much
remains to be learned about how the 2 receptor–mediated
events affect the progression of HF and about whether novel
sympatholytic agents can be developed to reduce the nor-
adrenergic drive while preserving the integrity of the sym-
pathetic nerve terminal function.
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